The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
Official Title: Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris
Study ID: NCT05799157
Brief Summary: This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
Detailed Description: Protocol 250-12951-201 is a planned Phase 2 study entitled "A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects with Verruca Vulgaris". Eligible subjects will be randomized into one of the three treatment groups (high dose, low dose, vehicle).
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Site 07, Fort Smith, Arkansas, United States
Site 16, San Diego, California, United States
Site 02, Plainfield, Indiana, United States
Site 13, Louisville, Kentucky, United States
Site 15, Baton Rouge, Louisiana, United States
Site 09, New Brighton, Minnesota, United States
Site 01, Anderson, South Carolina, United States
Site 06, Greenville, South Carolina, United States
Site 11, Knoxville, Tennessee, United States
Site 03, Arlington, Texas, United States
Site 04, Austin, Texas, United States
Site 10, College Station, Texas, United States
Site 12, Houston, Texas, United States
Site 05, Pflugerville, Texas, United States
Site 14, Norfolk, Virginia, United States
Site 08, Spokane, Washington, United States